Recent news on Palivizumab

MedImmune profits soar and AstraZeneca may spend again  -  May 1, 2007
Pharma Times (subscription),Revenues rose 15.4% to $574.8 million, driven by a strong increase in sales of Synagis (palivizumab), its paediatric vaccine for respiratory syncytial virus

U-turn at USA's MedImmune as board looks to sell up  -  Apr 13, 2007
Pharma Times (subscription),The jewel in MedImmune's crown is the respiratory treatment Synagis (palivizumab), though its sales for 2006 were flat at $1.1 billion.

MedImmune Announces Preliminary Results for 2007 First Quarter  -  Apr 11, 2007
Drug Newswire (press release),...it expects domestic and worldwide net sales growth of approximately 9-to-10 percent for Synagis(R) (palivizumab) over the same quarter in 2006.

MedImmune Predicts  -  Apr 9, 2007
Wall Street Journal (subscription),...expenses appear to be running lower than expected. Synagis's palivizumab is used to treat respiratory syncytial virus, which causes mild cold-like symptoms.

MedImmune Offer Comes In High: AstraZeneca To Pay $15.2 Billion  -  Apr 23, 2007
BioWorld Online,MedImmune in 2006 had revenues of about $1.28 billion, primarily on $1.1 billion in sales of Synagis (palivizumab), a monoclonal antibody indicated for the

AstraZeneca Plc Acquires MedImmune Inc for $15B  -  Apr 23, 2007
Playfuls.com,The company's marketed products include Synagis® (palivizumab), Ethyol® (amifostine), and FluMist® (Influenza Virus Vaccine Live, Intranasal),

AstraZeneca to buy MedImmune for $15.6 billion  -  Apr 23, 2007
Pharma Times (subscription),For its considerable outlay, AstraZeneca is getting access to the respiratory treatment Synagis (palivizumab), which had flat sales of $1.1 billion in 2006

RSV: lack of vaccine puts most vulnerable at risk  -  Apr 18, 2007
Pharmaceutical Business ReviewThe RSV market is currently dominated by MedImmune's prophylaxis Synagis (palivizumab), a recombinant human monoclonal antibody.

In Brief  -  Apr 3, 2007
Nature.com (subscription),Pennsylvania, Erbitux (cetuximab) from New York-based ImClone Systems and Synagis (palivizumab) from MedImmune of Gaithersburg, Maryland.

MedImmune rebuffs shareholder suggestion of a sale  -  Feb 19, 2007
Pharma Times (subscription),...its follow-on drug from the respiratory treatment Synagis (palivizumab) which had 2006 sales of $1.1 billion, and that delay might postpone the launch

Patent ruling aids MedImmune  -  Feb 22, 2007
Examiner.comKnown by the generic name palivizumab, Synagis is an indictable antibody that fights respiratory syncytial virus, according to the MedImmune Web site.

MedImmune Further Expands its Commercial Organization Expertise ...  -  Feb 20, 2007
PR Newswire (press release),...of marketing activities for Synagis(R) (palivizumab) as well as the commercialization of MedImmune's next-generation monoclonal antibody for RSV.

MedImmune Further Expands its Commercial Organization Expertise ...  -  Feb 20, 2007
Yahoo! News (press release)Jamie Harrell is responsible for leading the strategic direction of marketing activities for Synagis® (palivizumab) as well as the commercialization of

MedImmune Reports Financial Results For 2006  -  Feb 7, 2007
PR Newswire (press release),MedImmune's fourth quarter total revenues increased 7 percent to $529 million driven by gains in Synagis (palivizumab), FluMist (Influenza Vaccine Virus

AstraZeneca Acquires Arrow Therapeutics To Broaden Anti-Infective ...  -  Feb 2, 2007
Drug Newswire (press release),Currently, the only widely used intervention is MedImmune's monoclonal antibody, Synagis (palivizumab), which is used to prevent infection in high risk

Strong Lucentis sales help Genentech earnings soar  -  Jan 11, 2007
Pharma Times (subscription),...lawsuit challenging the validity of a key Genentech patent which is licensed to MedImmune in connection with its respiratory drug Synagis (palivizumab).

MedImmune Reconfirms 2009 Financial Targets of $2 Billion in ...  -  Dec 6, 2006
PR Newswire (press release),MedImmune expects continued growth from its largest currently marketed product, Synagis(R) (palivizumab), and is ready to implement a first-rate launch

MedImmune Fills Leadership Posts in Two Key Product Development Areas  -  Dec 5, 2006
Drug Newswire (press release),...for MedImmune's marketed infectious disease products, including Synagis(R) (palivizumab) and FluMist(R) (Influenza Virus Vaccine Live, Intranasal).

MedImmune Fills Leadership Posts in Two Key Product Development Areas  -  Dec 5, 2006
Yahoo! News (press release)...for MedImmune's marketed infectious disease products, including Synagis® (palivizumab) and FluMist® (Influenza Virus Vaccine Live, Intranasal).

MedImmune Announces Several Management Promotions  09 Nov 2006
...the company's proprietary enhanced yield process at FMC in 2001, which expanded the center's production capacity of Synagis® (palivizumab) from approximately ... -Yahoo! News (press release) Palivizumab (Synagis) Prophylaxis Appears to Protect Children With ...  Oct 10, 2006
...infection (LRTI) with respiratory syncytial virus (RSV) than the general pediatric population, but new research suggests that palivizumab (Synagis) treatment ... -DG News Numax(R) Achieves Primary Endpoint In Preliminary Analysis of Data ...  Nov 6, 2006
...caused by respiratory syncytial virus (RSV) in infants at high risk for serious RSV disease by 26 percent when compared to Synagis® (palivizumab). ... -Yahoo! News (press release) MedImmune Reports Financial Results for 2006 Third Quarter and ...  Oct 26, 2006
The revenue growth was fueled by an 11-percent increase in worldwide sales of Synagis (palivizumab) to $112 million; a 52-percent increase in sales of FluMist ... -Yahoo! News (press release) MedImmune Breaks Ground On New Biologics Manufacturing Facility  Sep 18, 2006
MedImmune's Synagis (palivizumab), the first monoclonal antibody approved by the US Food and Drug Administration (FDA) to help prevent an infectious disease ... -BioResearch Online

MedImmune in $250m biologics plant expansion  Sep 18, 2006
...expansion is the first phase of a four-stage construction project aimed at increasing capacity for childhood respiratory drug Synagis (palivizumab), the first ... -In-PharmaTechnologist.com

MedImmune Breaks Ground on Frederick (Maryland) Manufacturing Site ...  Sep 11, 2006
The expansion will increase MedImmune's manufacturing capacity for monoclonal antibodies (MAbs) such as Synagis(R) (palivizumab), which it introduced to the ... -PharmaLive.com

MedImmune Breaks Ground on New Biologics Manufacturing Facility in ...  Sep 13, 2006
MedImmune's Synagis® (palivizumab), the first monoclonal antibody approved by the US Food and Drug Administration (FDA) to help prevent an infectious disease ... -Yahoo! News

Infinity, MedImmune Enter Deal With $500M Potential  Aug 29, 2006
The company, which chalked up lighter than predicted revenues from the monoclonal antibody Synagis (palivizumab) for respiratory syncytial virus, "guided flat ... -BioWorld Online

MedImmune Backs FY06, FY09 Outlook - Update  -  Dec 6, 2006
Trading Markets,...leader in pediatric respiratory diseases, MedImmune expects continued growth from its largest currently marketed product, Synagis (palivizumab), and is ready ...

MedImmune Fills Leadership Posts in Two Key Product Development ...  -  Dec 5, 2006
Yahoo! News (press release)...of late-stage clinical programs and educational materials for MedImmune's marketed infectious disease products, including Synagis® (palivizumab) and FluMist ...

MedImmune Reconfirms 2009 Financial Targets of $2 Billion in ...  -  Dec 6, 2006
Yahoo! News (press release)...leader in pediatric respiratory diseases, MedImmune expects continued growth from its largest currently marketed product, Synagis® (palivizumab), and is ready ...

Infinity, MedImmune Enter Deal With $500M Potential  29 Aug 2006
The company, which chalked up lighter than predicted revenues from the monoclonal antibody Synagis (palivizumab) for respiratory syncytial virus, "guided flat ... -BioWorld Online

DME: Lifecycle management for biologics  Aug 2, 2006
...optimization' business strategy, by collaborating with US biotech MedImmune for the DME optimization of the anti-RSV monoclonal antibody Synagis (palivizumab). ... -PharmaLive.com

Directed molecular evolution: lifecycle management for biologics  Aug 3, 2006
...by collaborating with US biotech firm MedImmune for the DME optimization of the anti-respiratory syncytial virus (RSV) monoclonal antibody Synagis (palivizumab ... -PharmaLeader

MedImmune Reports 2006 Second-Quarter and Six-Month Financial ...  Jul 21, 2006
MedImmune's second-quarter results reflect the seasonal impact of two of its four marketed products, Synagis (palivizumab) and FluMist(R) (Influenza Virus ... -Drug Newswire



MedImmune Awarded $170 Million Five-Year Contract From US Health ...  May 10, 2006
...commented: "For the last 10 years, we have used our extensive experience with cell-based technology to manufacture Synagis(R) (palivizumab), a monoclonal ... - Webbolt Business News

MedImmune Reports Financial Results for First Quarter 2006  Apr 20, 2006
..."As described on our year-end earnings call in February, several factors impacted US sales of Synagis® (palivizumab) at the outset of the 2005-2006 ... - Yahoo! News





Zacks Analyst Blog Highlights: MedImmune, Inc., Mittal Steel, Cia ...  Mar 28, 2006
MedImmune's top line is driven by sales of a breakthrough monoclonal antibody called Synagis (palivizumab), developed for the prevention of serious lower ... - Business Wire



MedImmune Promotes Smullen to Senior Vice President, Sales  Feb 27, 2006
Smullen and his sales team successfully launched the first monoclonal antibody approved in the US for an infectious disease, Synagis® (palivizumab), which has ... - Yahoo! News

AS RSV Season Nears Its Peak, Parents of Premature Infants Need to ...  Feb 15, 2006
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus ... - Hispanic PR Wire,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional